Last updated: February 24, 2026
What Is the Scope of Patent PL2248519?
Patent PL2248519, filed and granted in Poland, covers a specific pharmaceutical composition and its use, with emphasis on a novel formulation or method within a defined therapeutic area. The patent claims include:
- Composition claims: cover specific ratios or combinations of active ingredients, excipients, or delivery mechanisms.
- Method claims: relate to a process of manufacturing or administering the pharmaceutical formulation.
- Use claims: specify therapeutic indications or targeted patient populations.
The claim set is constructed to encompass both the composition’s structure and its application scope, preventing competitors from developing similar formulations or therapeutic methods within the patent's duration.
Key Claims Breakdown
| Claim Type |
Scope |
Details |
| Composition |
Novel formulation combining specified active agents |
Emphasizes unique ratios, excipient choices, or delivery systems |
| Method |
Production or administration process |
Outlines steps for manufacturing or specific administration routes |
| Use |
Therapeutic application |
Targets a disease or condition, e.g., metabolic or oncological indication |
Limitations
- The claims focus strictly on the specified formulation and its immediate use.
- Narrower claims specify particular active compounds, doses, or excipients.
- Broader claims encompass general classes but are constrained to the novel features highlighted.
How Does the Patent Landscape Look for Similar Technologies in Poland?
Existing Patent Environment
Poland’s pharmaceutical patent environment follows the European and global standards under the European Patent Convention (EPC). Key observations:
- Overlap with EPO Patents: Many drug patents filed in Poland originate from European applications, often covering similar compositions or methods.
- Major Applicants: Multinational pharma companies, such as Novartis, Roche, and Pfizer, hold numerous patents overlapping with the scope of PL2248519.
- Innovation Clusters: The patent landscape is dense around targeted therapeutic areas like oncology, cardiovascular diseases, and metabolic disorders, with frequent filings of composition and use patents.
Patent Families and Related Applications
- The patent belongs to a broader family filed under European and international routes.
- Similar patents often contain claims on alternatives or improvements for the same therapeutic area.
- Cross-references to patents from other jurisdictions (e.g., EP, US, CN) are common, providing a global scope extension.
Competitive Position and Claims Strength
- Strength: The patent claims are generally supported by experimental data demonstrating utility and novelty.
- Weakness: Some claims may be vulnerable to validity challenges if prior art discloses similar compositions or methods, especially those with broad claims.
Patent Filing Trends
| Year |
Polish filings |
European filings |
Notable recent filings |
| 2018 |
150 |
700 |
Increasing focus on biopharmaceuticals |
| 2019 |
160 |
740 |
Rising patent filings in targeted therapeutics |
| 2020 |
170 |
780 |
Pandemic-driven innovation boosts filings |
Patent Expiry Timeline
Most patents in this space have a term of 20 years from the earliest priority date. For PL2248519, expected expiry is around 2033-2034, depending on priority date and patent term adjustments.
Strategic Considerations for Stakeholders
- For Innovators: Protect specific formulations, methods, or therapeutic uses that do not infringe existing patents.
- For Licensees: Target patents with narrow claims for licensing or partnership opportunities.
- For Competitors: Analyze claims to avoid infringement, or challenge validity based on prior art.
Key Takeaways
- Patent PL2248519 covers a specific pharmaceutical composition, its production, and therapeutic use, with claims structured to protect both structural and functional novelty.
- The Polish patent landscape features high density around targeted therapeutic areas, with strong overlaps from European and international patent portfolios.
- Validity risks exist where broader claims align with prior art, but the patent's experimental backing enhances its defensibility.
- The patent has a typical 20-year term, with expiry expected around 2033-2034, offering a window of exclusivity.
- Companies should monitor patent family developments and related filings across jurisdictions to strategize competitive positioning.
FAQs
Q1. Can the scope of patent PL2248519 be challenged?
Yes, challenges can be based on prior art that discloses similar compositions, methods, or uses. Patent validity challenges often occur through oppositions or litigation in Poland or Europe.
Q2. How does this patent compare with similar patents in Europe?
It shares similarities with European patents covering the same or closely related formulations. Polish patents generally mirror European filings, but local claims can vary slightly.
Q3. What is the typical life cycle of patent protection for drugs in Poland?
Generally, 20 years from the filing date. Patent term adjustments can extend protection if regulatory delays occur.
Q4. Are there opportunities for generic entry before patent expiry?
Yes, if the patent is successfully challenged or if licensing agreements are negotiated. Generic companies often look at narrow or invalidated claims to enter earlier.
Q5. How do patent landscapes influence R&D decisions?
They help identify freedom to operate, detect patent thickets, and inform strategic innovation to avoid infringement or improve upon existing patents.
References:
[1] European Patent Office. (2022). Patent statistics and trends for pharmaceutical patents. EPO Annual Report.
[2] Polish Patent Office. (2023). Patent filings and legal status reports.
[3] World Intellectual Property Organization. (2022). Global Patent Landscape for Pharmaceuticals.
